Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 11, Pages 434
Publisher
MDPI AG
Online
2018-11-14
DOI
10.3390/cancers10110434
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma
- (2018) Liang Zeng et al. Journal of Thoracic Oncology
- Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complex
- (2018) Minglei Yang et al. LUNG CANCER
- High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation
- (2018) Panwen Tian et al. LUNG CANCER
- EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib
- (2017) Uroosa Ibrahim et al. LUNG CANCER
- Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations
- (2017) Yi-Cheng Shen et al. LUNG CANCER
- A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
- (2017) Hai-Yan Tu et al. LUNG CANCER
- NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy
- (2017) Diego Kauffmann-Guerrero et al. RESPIRATION
- The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
- (2017) Chih-Jen Yang et al. BMC Pharmacology & Toxicology
- The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
- (2017) Chih-Jen Yang et al. BMC Pharmacology & Toxicology
- Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
- (2016) Chih-Jen Yang et al. OncoTargets and Therapy
- Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
- (2016) Chih-Jen Yang et al. OncoTargets and Therapy
- EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs
- (2015) Y. Kobayashi et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations
- (2015) Chao-Hua Chiu et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib
- (2015) Kuan-Li Wu et al. LUNG CANCER
- Correlation Between EGFR Mutation Status and Computed Tomography Features in Patients With Advanced Pulmonary Adenocarcinoma
- (2014) Jui-Sheng Hsu et al. JOURNAL OF THORACIC IMAGING
- Two Cases of Non–Small-Cell Lung Cancer with Rare Complex Mutation of EGFR Exon 18 But Different Response to Targeted Therapy
- (2014) Hélène Gauthier et al. Journal of Thoracic Oncology
- Rare EGFR Exon 20 S768I Mutation Predicts Resistance to Targeted Therapy: A Report of Two Cases
- (2014) Lalit Pallan et al. Journal of Thoracic Oncology
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
- (2012) Susumu Kobayashi et al. Journal of Thoracic Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
- (2009) R. K. Kancha et al. CLINICAL CANCER RESEARCH
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck
- (2008) Ilona Schwentner et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
- (2008) Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now